Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI

GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00780858

Acronym

Enrollment

662

Registered

2008-10-28

Start date

2008-10-31

Completion date

2011-03-31

Last updated

2015-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

GnRH antagonist, IUI

Brief summary

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Detailed description

The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Interventions

DRUGGanirelix

Ganirelix 0.25mg s.c every 24 h starting stimulation day 6

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* previous failed IUI cycle with premature luteinization

Exclusion criteria

* 39 years or older * not eligible for IUI (patent tubes, \> 3 million capacitated spermatozoa) * 4 previous IUI cycles

Design outcomes

Primary

Measure	Time frame
Pregnancy rate	2 weeks after intervention

Secondary

Measure	Time frame
premature luteinization	at the time of intervention

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026